口服加替沙星治疗社区获得性肺炎的临床观察

目的:观察口服加替沙星在治疗轻、中度社区获得性肺炎中的临床疗效和安全性。方法:选择轻、中度社区获得性肺炎患者41例,分两组。加替沙星组21例口服加替沙星7-14天(加替沙星400mg,Qd),对照组20例静脉点滴头孢三嗪7-14天(0.9%生理盐水100ml+头孢三嗪2g,静脉滴注,Qd),治疗前后给予血常规、肝肾功能、血糖、电解质、胸片、痰液细菌培养等检查。疗程结束作疗效及细菌清除率评价。结果:两组患者治疗前的基本情况无显著性差异(P>0.05),加替沙星组和对照组治疗有效率均为90%左右。加替沙星组痊愈率和病原茵清除率分别为57.1%和86.7%。对照组痊愈率和病原菌清除率分别为60%和92.3%。但统计学分析差异无显著性(P>0.05)。加替沙星组治疗前后肝肾功能、血糖、淀粉酶无显著性差异(P>0.05)。结论:口服加替沙星治疗轻、中度社区获得性肺炎,疗效可靠、安全性较好。

Clinical observation of oral administration of gatifloxacin in the treatment of community-acquired pneumonia

Aim;To observe the clinical efficacy and safety of oral administration of gatifloxacin in the treatment of mild to moderate community - acquired pneumonia. Methods: Forty - one patients with mild to moderate community - acquired pneumonia were divided randomly into two groups. One group took gatifloxacin orally for 7-14 days (400 mg, Qd) and control group were given ceftriaxone sodium intravenously (2 g, ivgtt, Qd). Blood routine, liver - kidney function, blood sugar, electrolyte, thorax X-ray examination, and sputum bacteria culture was measured before and after treatment respectively. Curative effect and bacteria elimination rate were evaluated after treatment. Results:The difference in general condition between the two groups was not significant ( P >0.05). Efficient rate of the two groups is about 90%. The recovery rate and pathogen elimination rate of gatifloxacin group were 57.1% and 86.7% respectively. Those of the control group were 60% and 92.3% respectively. The difference was not significant (P>0.05). There was no significant difference in terms of liver - kidney function and blood sugar and amylase level before and after gatifloxacin treatment (P > 0.05). Conclusion: Gatifloxacin is safe and efficient in the treatment of community - acquired pneumonia.